Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Free health clinics still drawing large crowds in cities across U.S.

Parade: A series of no-cost health care clinics are making their way across America. In Atlanta 1,050 volunteers gave their time to serve uninsured Americans who needed medical care. "The Atlanta mega-clinic was the sixth in a series that began in September. (The first was held in Houston in partnership with TV talk-show host and cardiothoracic surgeon Dr. Mehmet Oz.)

11 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Duchenne muscular dystrophy research at the University of Florida got a major boost with the award of $7.5 million in National Institutes of Health funding to study the use of magnetic resonance imaging in determining the natural progression of the disease.

10 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

New research examines coping and appraisal of disease-related pain

Growing evidence suggests how individuals cope with and appraise disease-related pain, such as arthritis or cancer, is related not only to their experience with pain but also to their physical and psychological functioning, according to new research presented here today in a plenary session talk at the American Pain Society's annual scientific meeting.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

DXA testing can prevent osteoporosis in at-risk women

Geisinger has exceeded the national benchmark for testing women who are at risk for developing osteoporosis - a silent and serious disease.

7 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

Increase in patient safety results in fewer negative medical outcomes: RAND study

Lisa Maas, executive director of Californians Allied for Patient Protection, issued the following statement in response to a recent study by the RAND Corporation which found that a reduction in the number of preventable patient injuries in California from 2001 to 2005 also corresponded to a drop in malpractice claims.

6 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

Southeast Pain Care offers non-addictive alternatives to pain relief

The untimely death of Michael Jackson has brought the issue of pain medication addiction to the forefront of American media recently. The good news for people suffering with pain is that there are several non-addictive alternatives to pain relief.

6 May 2010

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics, Inc. today announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at Digestive Disease Week 2010 in New Orleans, Louisiana.

6 May 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Transition Therapeutics reports increased revenue in third-quarter 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Free health clinics still drawing large crowds in cities across U.S.

Immunomedics third-quarter revenues increase to $10.7 million

Lexicon Pharmaceuticals first-quarter revenues down 61%

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

New research examines coping and appraisal of disease-related pain

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

DXA testing can prevent osteoporosis in at-risk women

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

Increase in patient safety results in fewer negative medical outcomes: RAND study

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Southeast Pain Care offers non-addictive alternatives to pain relief

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in